 Staurosporine
"Staurosporine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An indolocarbazole that is a potent PROTEIN KINASE C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)
| Descriptor ID |
D019311
|
| MeSH Number(s) |
D03.132.436.750 D03.438.473.144.750 D03.438.473.402.750 D03.494.148.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Staurosporine".
Below are MeSH descriptors whose meaning is more specific than "Staurosporine".
This graph shows the total number of publications written about "Staurosporine" by people in this website by year, and whether "Staurosporine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 0 | 1 | 1 | | 1992 | 0 | 2 | 2 | | 1993 | 0 | 3 | 3 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 3 | 3 | | 1997 | 1 | 1 | 2 | | 1998 | 1 | 2 | 3 | | 1999 | 0 | 4 | 4 | | 2000 | 0 | 5 | 5 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2004 | 0 | 5 | 5 | | 2005 | 1 | 1 | 2 | | 2009 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Staurosporine" by people in Profiles.
-
Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, Panina E, Blätte TJ, Herzig J, Skambraks S, Rücker FG, Gaidzik VI, Paschka P, Fiedler W, Salih HR, Wulf G, Schroeder T, Lübbert M, Schlenk RF, Thol F, Heuser M, Larson RA, Ganser A, Stunnenberg HG, Minucci S, Stone RM, Bloomfield CD, Döhner H, Döhner K, Bullinger L. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021 06 03; 137(22):3093-3104.
-
Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Voso MT, Klisovic RB, Galinsky I, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Döhner H, Stone RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551.
-
Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H, Bloomfield CD, Lo-Coco F. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 10 13; 4(19):4945-4954.
-
Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018 02 27; 2(4):444-453.
-
Stone RM, Larson RA, Döhner H. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 11 09; 377(19):1903.
-
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 08 03; 377(5):454-464.
-
Wang Y, Buggia-Prévot V, Zavorka ME, Bleackley RC, MacDonald RG, Thinakaran G, Kar S. Overexpression of the Insulin-Like Growth Factor II Receptor Increases ß-Amyloid Production and Affects Cell Viability. Mol Cell Biol. 2015 Jul; 35(14):2368-84.
-
Woolley JF, Naughton R, Stanicka J, Gough DR, Bhatt L, Dickinson BC, Chang CJ, Cotter TG. H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling. PLoS One. 2012; 7(7):e34050.
-
Loor G, Kondapalli J, Schriewer JM, Chandel NS, Vanden Hoek TL, Schumacker PT. Menadione triggers cell death through ROS-dependent mechanisms involving PARP activation without requiring apoptosis. Free Radic Biol Med. 2010 Dec 15; 49(12):1925-36.
-
Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell. 2009 Nov 13; 36(3):487-99.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
- Cytarabine
- Leukemia, Myeloid
- Piperazines
- Pyrimidines
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Neoplasms, Second Primary
- Hematopoietic Stem Cell Transplantation
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
_
Top Journals
Top journals in which articles about this concept have been published.
|